SIRT2抑制了人类β细胞的增殖:治疗机会和下一个挑战
The Journal of clinical investigation
|October 1, 2025
概括
研究人员发现,抑制Sirtuin 2 (SIRT2) 可以促进胰腺β细胞的增殖. 这一发现为再生医学在糖尿病治疗中提供了潜在的新途径.
科学领域:
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
- 再生医学是一种再生医学.
背景情况:
- 糖尿病的特点是失去产生胰岛素的β细胞.
- 目前的治疗策略侧重于替换或再生β细胞.
研究的目的:
- 为了研究sirtuin 2 (SIRT2) 在调节β细胞增殖中的作用.
- 探索SIRT2抑制对β细胞再生的潜力.
主要方法:
- 人类和小鼠β细胞中SIRT2的药理和遗传抑制.
- 对β细胞增殖和细胞循环进入的分析.
- 研究SIRT2的点,包括线粒体氧化酸化 (OxPhos) 酶.
主要成果:
- SIRT2 作为抑制β细胞增殖的一种作用.
- 抑制SIRT2诱导人类和小鼠β细胞重新进入细胞循环.
- SIRT2主要向线粒体OxPhos酶,尽管将其与细胞循环进入联系的机制目前尚不清楚.
结论:
- 抑制SIRT2是一种诱导β细胞增殖的有希望的策略.
- 需要进一步的研究,以阐明SIRT2影响OxPhos和细胞循环进入的确切机制.
- SIRT2抑制剂代表了用于β细胞再生疗法的潜在新类药物.
相关概念视频
Tissue Renewal without Stem Cells
2.1K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
However, failure of such a system...
2.1K
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Somatic to iPS Cell Reprogramming
2.6K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.6K


